Advances in pharmacotherapy for primary biliary cholangitis
The pathogenesis of primary biliary cholangitis (PBC) remains unclear. Ursodeoxycholic acid (UDCA) is currently the only drug approved by the Food and Drug Administration for the treatment of PBC, but some patients have a poor response to UDCA. New therapies can be considered for these patients. Thi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2017-06-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8280 |